表紙
市場調查報告書
商品編碼
1029933

中東和非洲Hunter氏症治療市場-到 2028 年的行業趨勢和預測

Middle East and Africa Hunter Syndrome Treatment Market- Industry Trends and Forecast to 2028

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 100 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

中東/非洲Hunter氏症治療市場預計將從 2021 年到 2028 年以 7.0% 的複合年增長率增長。

本報告調查和分析了中東和非洲的Hunter氏症治療市場,並分析了新的治療方法、監管指南 (MPS II)、促進因素、抑制因素、市場機會、COVID-19 影響和嚴重程度,按類型,按複雜性,按最終用戶,按分銷渠道,按地區,市場信息,公司情況,SWOT 分析,公司簡介。

目錄

第 1 章介紹

第 2 章市場細分

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章 Hunter氏症的新療法

  • 治療:DNL310
  • 治療:JR141
  • 治療:TAK-609/SHP609/HGT-2310
  • 治療:RGX-121
  • 治療:SB-913
  • 治療:AVR-RD-05
  • 治療:ODIPARCIL
  • 治療:AGT-181
  • 治療:EGT-301

第 6 章Hunter氏症(MPS II)監管指南

  • Hunter氏症:美國監管框架
  • Hunter氏症:歐洲監管框架
  • Hunter氏症:亞太地區監管框架

第 7 章流行病學

第 8 章市場概覽

  • 促進因素
    • Hunter氏症患病率增加
    • 越來越多地採用基因療法
    • 增加政府主動性
    • 增加公共和私營部門的資金
    • 技術進步
  • 抑制因素
    • 目前治療的副作用
    • 政府對 MPSII 治療開發的嚴格規定
    • 人們對Hunter氏症的存在缺乏認識
    • 與 MPS II 治療相關的高成本
  • 市場機會
    • 對疾病特異性治療的高需求
    • 大公司合作、併購
    • 新途徑藥物的存在
  • 挑戰
    • 當前的治療限制
  • 不當的兌換政策

第 9 章中東/非洲Hunter氏症治療市場:COVID-19 的影響

  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第 10 章中東/非洲Hunter氏症治療市場:按嚴重程度

  • 概述
  • 中度至重度
  • 輕度至中度

第 11 章中東/非洲Hunter氏症治療市場:按類型

  • 概述
  • □替代療法
    • ELAPRASE + TAK-609
    • 漢特□
    • IZCARGO
  • 幹細胞移植
    • 臍帶移植
    • 骨髓移植
  • 手術治療
    • 心臟瓣膜置換術
    • 氣管切開術
    • 氣道正壓裝置
    • 關節攣縮
    • 腹疝手術
    • 其他
  • 其他

第 12 章中東/非洲Hunter氏症治療市場:併發症

  • 概述
  • 呼吸系統疾病
  • 神經紊亂
  • 心血管
  • 肌肉骨骼
  • 胃腸道疾病
  • 眼科
  • 聽力學
  • 牙科
  • 其他

第 13 章中東/非洲Hunter氏症治療市場:按最終用戶

  • 概述
  • 醫院
  • 診所
  • 醫療保健
  • 其他

第 14 章中東/非洲Hunter氏症治療市場:按分銷渠道

  • 概述
  • 醫院藥房
  • 零售藥店
  • 網上藥店
  • 其他

第 15 章中東/非洲Hunter氏症治療市場:按地區

  • 中東/非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 埃及
    • 以色列
    • 科威特
    • 其他 中東和非洲其他地區

第 16 章中東/非洲Hunter氏症治療市場:企業現狀

  • 企業市場份額分析:中東/非洲

第 17 章SWOT分析

第 18 章公司簡介

  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • GREEN CROSS CORP.
  • ABBOTT
  • AVROBIO, INC.
  • BD
  • CANBRIDGE LIFE SCIENCES LTD.
  • DENALI THERAPEUTICS
  • HOMOLOGY MEDICINES, INC.
  • INVENTIVA
  • JASPER THERAPEUTICS, INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • JOHNSON & JOHNSONS SERVICES, INC.
  • MEDTRONIC
  • NOVARTIS AG
  • ON-X LIFE TECHNOLOGIES(A SUBSIDIARY OF CRYOLIFE, INC.)
  • PFIZER INC.
  • REGENXBIO INC.
  • SANGAMO THERAPEUTICS
  • STRYKER
  • UCB S.A.

第 19 章問卷

第 20 章相關報導

目錄

Middle East and Africa hunter syndrome treatment market is projected to register a healthy CAGR of 7.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Middle East and Africa Hunter Syndrome Treatment Market, By Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of hunter syndrome treatment market are:

  • Increasing prevalence of hunter syndrome
  • Rising adoption of gene therapy
  • Increasing government initiatives
  • Increasing fund by public and private organizations

Market Players:

The key market players for Middle East and Africa hunter syndrome treatment market are listed below:

  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Medtronic
  • Abbott
  • BD
  • Novartis AG
  • Stryker

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 SEVERITY LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET END USER COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 EMERGING TREATMENTS FOR HUNTER SYNDROME

  • 5.1 TREATMENT: DNL310
  • 5.2 TREATMENT: JR141
  • 5.3 TREATMENT: TAK-609/SHP609/HGT-2310
  • 5.4 TREATMENT: RGX-121
  • 5.5 TREATMENT: SB-913
  • 5.6 TREATMENT: AVR-RD-05
  • 5.7 TREATMENT: ODIPARCIL
  • 5.8 TREATMENT: AGT-181
  • 5.9 TREATMENT: EGT-301

6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)

  • 6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME

7 EPIDEMIOLOGY

8 MARKET OVERVIEW

  • 8.1 DRIVERS
    • 8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
    • 8.1.2 RISING ADOPTION OF GENE THERAPY
    • 8.1.3 INCREASING GOVERNMENT INITIATIVES
    • 8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
    • 8.1.5 TECHNOLOGICAL ADVANCEMENTS
  • 8.2 RESTRAINTS
    • 8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
    • 8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
    • 8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
    • 8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
  • 8.3 OPPORTUNITIES
    • 8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
    • 8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
    • 8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
  • 8.4 CHALLENGES
    • 8.4.1 LIMITATIONS OF CURRENT TREATMENT
  • 8.5 IMPROPER REIMBURSEMENT POLICIES

9 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET

  • 9.1 IMPACT ON PRICE
  • 9.2 IMPACT ON DEMAND
  • 9.3 IMPACT ON SUPPLY CHAIN
  • 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 9.5 CONCLUSION

10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MODERATE TO SEVERE
  • 10.3 MILD TO MODERATE

11 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 ENZYME REPLACEMENT THERAPY
    • 11.2.1 ELAPRASE + TAK-609
    • 11.2.2 HUNTERASE
    • 11.2.3 IZCARGO
  • 11.3 STEM CELL TRANSPLANT
    • 11.3.1 UMBILICAL CORD TRANSPLANT
    • 11.3.2 BONE MARROW TRANSPLANT
  • 11.4 SURGICAL TREATMENT
    • 11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
    • 11.4.2 TRACHEOSTOMY
    • 11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
    • 11.4.4 JOINT CONTRACTURES
    • 11.4.5 ABDOMINAL HERNIA SURGERY
    • 11.4.6 OTHERS
  • 11.5 OTHERS

12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS

  • 12.1 OVERVIEW
  • 12.2 RESPIRATORY DISORDERS
  • 12.3 NEUROLOGICAL DISORDERS
  • 12.4 CARDIOVASCULAR
  • 12.5 MUSCULOSKELETAL
  • 12.6 GASTROINTESTINAL DISORDERS
  • 12.7 OPHTHALMIC
  • 12.8 AUDIOLOGIC
  • 12.9 DENTAL
  • 12.10 OTHERS

13 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 HOSPITALS
  • 13.3 CLINICS
  • 13.4 HOME HEALTHCARE
  • 13.5 OTHERS

14 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 HOSPITAL PHARMACY
  • 14.3 RETAIL PHARMACY
  • 14.4 ONLINE PHARMACY
  • 14.5 OTHERS

15 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION

  • 15.1 MIDDLE EAST & AFRICA
    • 15.1.1 SOUTH AFRICA
    • 15.1.2 SAUDI ARABIA
    • 15.1.3 U.A.E.
    • 15.1.4 EGYPT
    • 15.1.5 ISRAEL
    • 15.1.6 KUWAIT
    • 15.1.7 REST OF MIDDLE EAST & AFRICA

16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 GREEN CROSS CORP.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 ABBOTT
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 PRODUCT PORTFOLIO
    • 18.3.4 RECENT DEVELOPMENTS
  • 18.4 AVROBIO, INC.
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 PRODUCT PORTFOLIO
    • 18.4.3 RECENT DEVELOPMENTS
  • 18.5 BD
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 PRODUCT PORTFOLIO
    • 18.5.4 RECENT DEVELOPMENT
  • 18.6 CANBRIDGE LIFE SCIENCES LTD.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 PRODUCT PORTFOLIO
    • 18.6.3 RECENT DEVELOPMENTS
  • 18.7 DENALI THERAPEUTICS
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 PRODUCT PORTFOLIO
    • 18.7.4 RECENT DEVELOPMENTS
  • 18.8 HOMOLOGY MEDICINES, INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 TECHNOLOGY PORTFOLIO
    • 18.8.4 RECENT DEVELOPMENTS
  • 18.9 INVENTIVA
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 PRODUCT PORTFOLIO
    • 18.9.4 RECENT DEVELOPMENTS
  • 18.10 JASPER THERAPEUTICS, INC.
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 JCR PHARMACEUTICALS CO., LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 PRODUCT PORTFOLIO
    • 18.11.4 RECENT DEVELOPMENTS
  • 18.12 JOHNSON & JOHNSONS SERVICES, INC.
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 PRODUCT PORTFOLIO
    • 18.12.4 RECENT DEVELOPMENTS
  • 18.13 MEDTRONIC
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 PRODUCT PORTFOLIO
    • 18.13.4 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 PRODUCT PORTFOLIO
    • 18.14.4 RECENT DEVELOPMENTS
  • 18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 PRODUCT PORTFOLIO
    • 18.15.4 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 REVENUE ANALYSIS
    • 18.16.3 PRODUCT PORTFOLIO
    • 18.16.4 RECENT DEVELOPMENTS
  • 18.17 REGENXBIO INC.
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 PRODUCT PORTFOLIO
    • 18.17.4 RECENT DEVELOPMENTS
  • 18.18 SANGAMO THERAPEUTICS
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENT
  • 18.19 STRYKER
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 PRODUCT PORTFOLIO
    • 18.19.4 RECENT DEVELOPMENTS
  • 18.20 UCB S.A.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 PRODUCT PORTFOLIO
    • 18.20.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 2 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 MIDDLE EAST AND AFRICA MILD TO MODERATE IN MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 5 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 7 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 9 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 13 MIDDLE EAST AND AFRICA RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 MIDDLE EAST AND AFRICA MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 17 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 MIDDLE EAST AND AFRICA OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 MIDDLE EAST AND AFRICA AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 MIDDLE EAST AND AFRICA DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 22 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • TABLE 23 MIDDLE EAST AND AFRICA HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 MIDDLE EAST AND AFRICA CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 25 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • TABLE 28 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
  • TABLE 33 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 34 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 35 MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 36 MIDDLE EAST & AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 41 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 42 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 43 SOUTH AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 44 SOUTH AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 45 SOUTH AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 46 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 47 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 48 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 49 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 50 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 51 SAUDI ARABIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 52 SAUDI ARABIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 53 SAUDI ARABIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 54 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 55 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 56 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 57 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 58 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 59 U.A.E. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 60 U.A.E. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 61 U.A.E. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 62 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 63 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 64 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 65 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 66 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 67 EGYPT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 68 EGYPT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 69 EGYPT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 70 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 71 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 72 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 73 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 74 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 75 ISRAEL ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 76 ISRAEL STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 77 ISRAEL SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 78 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 79 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 80 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 81 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 82 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 83 KUWAIT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 84 KUWAIT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 85 KUWAIT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 86 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 87 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 88 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 89 REST OF MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 2 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
  • FIGURE 3 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
  • FIGURE 9 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
  • FIGURE 10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR HUNTER SYNDROME TREATMENT PRODUCT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
  • FIGURE 16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
  • FIGURE 19 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • FIGURE 20 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • FIGURE 21 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
  • FIGURE 22 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
  • FIGURE 23 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 24 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 25 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
  • FIGURE 26 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)